Literature DB >> 30476938

Metastatic Calcinosis Cutis Associated With a Selective FGFR Inhibitor.

David R Carr1, Llana Pootrakul1, Hui-Zi Chen2, Catherine G Chung1,3.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 30476938     DOI: 10.1001/jamadermatol.2018.4070

Source DB:  PubMed          Journal:  JAMA Dermatol        ISSN: 2168-6068            Impact factor:   10.282


× No keyword cloud information.
  5 in total

Review 1.  Role of Phosphate in Biomineralization.

Authors:  Sanjay Kumar Bhadada; Sudhaker D Rao
Journal:  Calcif Tissue Int       Date:  2020-07-25       Impact factor: 4.333

Review 2.  Potentially life‑threatening severe cutaneous adverse reactions associated with tyrosine kinase inhibitors (Review).

Authors:  Emily L Coleman; Brianna Olamiju; Jonathan S Leventhal
Journal:  Oncol Rep       Date:  2020-12-24       Impact factor: 3.906

3.  Metastatic Calcinosis Cutis Secondary to Selective Fibroblast Growth Factor Receptor Inhibitor: Rapid and Complete Regression after Blood Phosphate Normalization and Drug Withdrawal.

Authors:  Daniel Lopez-Castillo; Alvaro March-Rodriguez; Alejo Rodriguez-Vida; Ramon M Pujol; Sonia Segura
Journal:  Acta Derm Venereol       Date:  2020-03-12       Impact factor: 3.875

Review 4.  Fibroblast growth factor receptors in cancer: genetic alterations, diagnostics, therapeutic targets and mechanisms of resistance.

Authors:  Melanie A Krook; Julie W Reeser; Gabrielle Ernst; Hannah Barker; Max Wilberding; Gary Li; Hui-Zi Chen; Sameek Roychowdhury
Journal:  Br J Cancer       Date:  2020-12-03       Impact factor: 7.640

Review 5.  Dermatologic Adverse Events Associated with Selective Fibroblast Growth Factor Receptor Inhibitors: Overview, Prevention, and Management Guidelines.

Authors:  Mario E Lacouture; Vincent Sibaud; Milan J Anadkat; Benjamin Kaffenberger; Jonathan Leventhal; Kathleen Guindon; Ghassan Abou-Alfa
Journal:  Oncologist       Date:  2020-10-28       Impact factor: 5.837

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.